Table 3.

Adjusted OR and 95% CI for the associations between aspirin use, frequency, and duration and NSCLC risk in the NCI-Maryland NSCLC Case–Control Study

AllEAAA
Aspirin useOR (95% CI)POR (95% CI)POR (95% CI)P
 NoReferenceReferenceReference
 Yes0.69 (0.56–0.86)0.0010.71 (0.54–0.93)0.010.59 (0.40–0.87)0.008
Daily aspirin use
 NeverReferenceReferenceReference
 <1 tablet per day0.51 (0.24–1.08)0.080.31 (0.12–0.77)0.0042.08 (0.55–7.86)0.28
 ≥ 1 tablet per day0.70 (0.56–0.87)0.0010.75 (0.57–0.98)0.030.56 (0.37–0.82)0.004
 Trend0.0010.030.004
Duration of aspirin use
 NeverReferenceReferenceReference
 <3 years0.70 (0.49–0.99)0.050.58 (0.37–0.91)0.020.85 (0.46–1.58)0.61
 ≥3 years0.68 (0.54–0.87)0.0020.72 (0.54–0.97)0.030.54 (0.34–0.84)0.007
 Trend0.0010.020.008
  • NOTE: Adjusted for age, gender, smoking, pack-years, education, family history of lung cancer, marital status, year of interview, genetic ancestry, and use of Tylenol and other NSAIDs.

  • Bold values denote statistical significance.